Diethylcarbamazine

CHEMBL684 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
199.3 g/mol
LogP
0.3
Phase
4

An antiparasitic medication used to treat lymphatic filariasis (elephantiasis), loiasis, and tropical pulmonary eosinophilia caused by filarial worms. It works by killing the microfilariae stage of the parasites and immobilizing adult worms, making them susceptible to the immune system. Severe reactions can occur when large numbers of parasites are killed rapidly.

Khối lượng phân tử

199,2900 g/mol

LogP

0,30

TPSA

26,80 Ų

Lipinski RO5

Đạt

Cơ chế tác dụng

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN(CC)C(=O)N1CCN(C)CC1

InChI

InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3

Molecular Formula

C10H21N3O

HBD / HBA

- / 2

Liên kết có thể quay

2

Nguyên tử nặng

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

An antiparasitic medication used to treat lymphatic filariasis (elephantiasis), loiasis, and tropical pulmonary eosinophilia caused by filarial worms. It works by killing the microfilariae stage of the parasites and immobilizing adult worms, making them susceptible to the immune system. Severe reactions can occur when large numbers of parasites are killed rapidly.

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Yes, Diethylcarbamazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL684. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3052. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.